Dataset Information


Burghaus2011 - Simulating Rivaroxaban effects on blood coagulation

ABSTRACT: Another mathematical model of blood coagulation.

SUBMITTER: Matthew Roberts  

PROVIDER: MODEL1805140001 | BioModels | 2018-05-21


altmetric image


Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.

Burghaus Rolf R   Coboeken Katrin K   Gaub Thomas T   Kuepfer Lars L   Sensse Anke A   Siegmund Hans-Ulrich HU   Weiss Wolfgang W   Mueck Wolfgang W   Lippert Joerg J  

PloS one 20110422 4

Rivaroxaban is an oral, direct Factor Xa inhibitor approved in the European Union and several other countries for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery and is in advanced clinical development for the treatment of thromboembolic disorders. Its mechanism of action is antithrombin independent and differs from that of other anticoagulants, such as warfarin (a vitamin K antagonist), enoxaparin (an indirect thrombin/Factor Xa inh  ...[more]

Similar Datasets

2019-07-10 | BIOMD0000000747 | BioModels
2018-07-18 | MODEL1807180005 | BioModels
2018-07-18 | MODEL1807180004 | BioModels
2019-03-26 | PXD012768 | Pride
2018-06-27 | MODEL1806270001 | BioModels
2018-06-27 | BIOMD0000000951 | BioModels
2019-07-12 | MODEL1907120001 | BioModels
2019-07-05 | BIOMD0000000740 | BioModels
2018-07-23 | MODEL1807230001 | BioModels
2018-10-26 | PXD004443 | Pride